Day 1: Thursday August 24, 2023
09:45-10:00: Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)
Session 1: Chairs: Bjørn Tore Gjertsen, Jeffrey Tyner
10:00-10:30: NAMLG Keynote Lecture
Sören Lehmann: Chromatin organization – the next step in the characterization of AML
10:30-10:50: Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy
10:50-11:10: Krister Wennerberg: Repurposing through drug sensitivity screen in AML
11:10-11:30: Caroline Heckman: Contextual factors in drug sensitivity screen
11:30-11:50: Päivi Östling: Harmonization of Drug sensitivity Screen
Session 2: Chair: Mika Kontro, Kim Theilgaard-Mönch
11:50-12:20: Martin Jädersten: Real world use of venetoclax
12:20-12:40: Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx
12:40-13:30: NAMLG Keynote Lecture
Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development
13:30-14:30: LUNCH BREAK
Session 3: Chairs: Sören Lehmann, Oscar Brück
14:30-14:50: Tom Erkers: Data driven hallmarks in AML
14:50-15:10: Thoas Fioretos: Harnessing the Power of Genomics for Improved Precision Medicine
15:10-15:40 COFFEE BREAK
Session 4: Chairs: Bjørn Tore Gjertsen, Karl-Johan Malmberg
15:40-16:10: Mohn Research Centre for Regenerative Medicine (MRCRM) Keynote Lecture
Gunnar Kvalheim: WT1/PRAME RNA-loaded dendritic cell vaccine in AML
16:10-16:30: Karl-Johan Malmberg: NK immunotherapy in AML
16:30-16:50: Sébastien Walchli: CAR T in AML
18:10-19:15 RECEPTION IN HAAKONSHALLEN, BERGEN MUNCIPALITY
19:45 CONFERENCE DINNER
______________________________________________________________________
Day 2: Friday August 25, 2023
Session 5: Chairs: Anne-Sophie von Krogh, Marianne Tang Severinsen
08:15-08:45: Gunnar Juliusson: Challenges of the new AML classifications and guidelines
08:45 – 09:00: Discussion
09:00 – 09:30: NAMLG Keynote Lecture
Gerwin Huls: AML therapy backbone and the future of targeted therapies
09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring
09:50 – 10:10: Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML
10:10 – 10:40: Oscar Brück: Data Lake and collection of data for real world epidemiology
10:40 – 11:10 COFFEE BREAK
Session 6: Chairs: Caroline Heckman, JJ Schuringa
11:10 – 11:40: NAMLG Keynote Lecture
J.J. Schuringa: Tumor-stromal interactions in AML
11:40 – 12:00: Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid malignancies
12:00 –12:30: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies
12:30 – 13:30: LUNCH BREAK
Session 7: Chairs: James Lorens, Krister Wennerberg
13:30 – 13:45: James Lorens: Axl as therapeutic target in cancer
13:45 – 14:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Sonia Loges: AXL in AML
14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Uwe Platzbecker: Bemcentinib and Axl in MDS and AML.
Session 8: Chairs: Jean Christoph Bourdon; Andrea Lenartova
14:45 – 15:05: Jean Cristoph Bourdon: p53 and its isoforms in cancer
15:05 – 15:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Eva Hellström-Lindberg: TP53 mutations in MDS and AML
15:45 – 16:15 COFFEE BREAK
Session 9: Chair: Pia Ettala, Vladimir Lazarevic
16:15 – 16:45: Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration
16:45 – 17:00: Closing remarks: Mika Kontro, Secretary, NAMLG